Literature DB >> 24759138

Inflammation-associated activation of coagulation and immune regulation by the protein C pathway.

Hartmut Weiler1.   

Abstract

The inflammation-induced activation of the protein C pathway provides negative feedback inhibition of coagulation and exerts coagulation-independent anti-inflammatory and cytoprotective effects. The balance between these activities of aPC modulates the outcome of diverse inflammatory diseases such as encephalitis, diabetes, and sepsis; and is affected by naturally occurring aPC-resistance of coagulation factor V Leiden.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Factor V Leiden; Inflammation; Protein C

Mesh：

Substances：

Year:  2014        PMID： 24759138      PMCID： PMC4060429          DOI： 10.1016/j.thromres.2014.03.015

Source DB:  PubMed          Journal:  Thromb Res        ISSN： 0049-3848            Impact factor:   3.944


  15 in total

1.  Inhibition of endogenous activated protein C attenuates experimental autoimmune encephalomyelitis by inducing myeloid-derived suppressor cells.

Authors:  Leah M Alabanza; Naomi L Esmon; Charles T Esmon; Margaret S Bynoe
Journal:  J Immunol       Date:  2013-08-30       Impact factor: 5.422

2.  Role of the factor V Leiden mutation in septic peritonitis assessed in factor V Leiden transgenic mice.

Authors:  Lois W Brüggemann; Saskia H H F Schoenmakers; Angelique P Groot; Pieter H Reitsma; C Arnold Spek
Journal:  Crit Care Med       Date:  2006-08       Impact factor: 7.598

3.  Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice.

Authors:  Edward Kerschen; Irene Hernandez; Mark Zogg; Shuang Jia; Martin J Hessner; Jose A Fernandez; John H Griffin; Claudia S Huettner; Francis J Castellino; Hartmut Weiler
Journal:  J Clin Invest       Date:  2010-08-16       Impact factor: 14.808

4.  Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis.

Authors:  Berend Isermann; Ilya A Vinnikov; Thati Madhusudhan; Stefanie Herzog; Muhammed Kashif; Janusch Blautzik; Marcus A F Corat; Martin Zeier; Erwin Blessing; Jun Oh; Bruce Gerlitz; David T Berg; Brian W Grinnell; Triantafyllos Chavakis; Charles T Esmon; Hartmut Weiler; Angelika Bierhaus; Peter P Nawroth
Journal:  Nat Med       Date:  2007-11-04       Impact factor: 53.440

5.  Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia.

Authors:  Bryce A Kerlin; S Betty Yan; Berend H Isermann; John T Brandt; Rashmi Sood; Bruce R Basson; David E Joyce; Hartmut Weiler; Jean-Francois Dhainaut
Journal:  Blood       Date:  2003-07-17       Impact factor: 22.113

6.  Influence of Factor V Leiden on susceptibility to and outcome from critical illness: a genetic association study.

Authors:  Thomas Benfield; Karen Ejrnaes; Klaus Juul; Christian Østergaard; Jannik Helweg-Larsen; Nina Weis; Lea Munthe-Fog; Gitte Kronborg; Marianne Ring Andersen; Anne Tybjaerg-Hansen; Børge G Nordestgaard; Peter Garred
Journal:  Crit Care       Date:  2010-03-05       Impact factor: 9.097

7.  Impact of the factor V Leiden mutation on the outcome of pneumococcal pneumonia: a controlled laboratory study.

Authors:  Marcel Schouten; Cornelis van't Veer; Joris J T H Roelofs; Marcel Levi; Tom van der Poll
Journal:  Crit Care       Date:  2010-08-03       Impact factor: 9.097

8.  Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets.

Authors:  May H Han; Sun-Il Hwang; Dolly B Roy; Deborah H Lundgren; Jordan V Price; Shalina S Ousman; Guy Haskin Fernald; Bruce Gerlitz; William H Robinson; Sergio E Baranzini; Brian W Grinnell; Cedric S Raine; Raymond A Sobel; David K Han; Lawrence Steinman
Journal:  Nature       Date:  2008-02-17       Impact factor: 49.962

Review 9.  Coagulation factor V and thrombophilia: background and mechanisms.

Authors:  Kenneth Segers; Björn Dahlbäck; Gerry A F Nicolaes
Journal:  Thromb Haemost       Date:  2007-09       Impact factor: 5.249

10.  Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C.

Authors:  Edward J Kerschen; José A Fernandez; Brian C Cooley; Xia V Yang; Rashmi Sood; Laurent O Mosnier; Francis J Castellino; Nigel Mackman; John H Griffin; Hartmut Weiler
Journal:  J Exp Med       Date:  2007-09-24       Impact factor: 14.307
View more
  1 in total

1.  Circulating activated protein C in thrombophilia carriers.

Authors:  Thijs E van Mens; Joost C M Meijers; Saskia Middeldorp
Journal:  J Thromb Thrombolysis       Date:  2017-04       Impact factor: 2.300
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.